Insights - Synageva BioPharma Corp (GEVA) announced the pricing of its secondary offering after the bell on Wednesday. The company priced 2.0 million shares, or 2.3 million including the … Continue Reading
PremiumResearch - With the stock hitting previous support, we think its time to own Durect (DRRX) yet again.
PremiumInsights - QLT Inc (QLTI) reported positive retreatment data on Thursday for its synthetic oral retinoid compound QLT091001 (-001), indicated for the orphan designated Leber Congenital Amaurosis … Continue Reading
Read nowResearch - Forward earnings potential drastically undervalued and could mean upside into the double digits for the long-term investor. Stock traded at $4-5 before key negative inflection … Continue Reading
PremiumInsights - Arrowhead Research (ARWR), which develops targeted RNAi therapeutics, pulled down gross proceeds of $104 million on Wednesday through the sale of its common stock, a … Continue Reading
Read nowInsights - It looks like a risk associated with some approved antibiotics may not be a concern for Cempra’s (CEMP) own late-stage candidate, solithromycin. Cempra announced on … Continue Reading
Read nowResearch - BioDelivery Sciences (BDSI) and partner Endo Health Solutions (ENDP) announced on the 23rd that the second of three phase 3 trials testing one of its lead drug candidates, BEMA buprenorphine, … Continue Reading
Read now
